In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price target of $4.00. The company’s shares opened today at $0.72.
According to TipRanks, White is an analyst with an average return of -6.3% and a 31.59% success rate. White covers the Healthcare sector, focusing on stocks such as G1 Therapeutics, Spectrum Pharmaceuticals, and TRACON Pharmaceuticals.
SAB Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.87 and a one-year low of $0.50. Currently, SAB Biotherapeutics has an average volume of 67.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
- SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
- SAB Biotherapeutics CMO to present on biologics in immunology
- SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
- SAB Biotherapeutics announces results from project using DiversitAb platform
- SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
